70416-53-4

Usage

Uses

Used in Pharmaceutical Industry:
5-Fornyl-3-pyridinecarbonitrile is used as a key intermediate in the synthesis of various pharmaceutical compounds for its ability to contribute to the development of new drugs with potential therapeutic applications.
Used in Agrochemical Industry:
In the agrochemical sector, 5-Fornyl-3-pyridinecarbonitrile serves as an intermediate in the production of agrochemicals, playing a crucial role in the creation of pesticides and other agricultural chemicals to enhance crop protection and yield.

InChI:InChI=1/C7H4N2O/c8-2-6-1-7(5-10)4-9-3-6/h1,3-5H

Upstream product

• 135124-71-9 5-(hydroxymethyl)pyridine-3-carbonitrile 
• 70416-52-3 5-[1,3]dioxolan-2-yl-nicotinonitrile 
• 113118-81-3 5-bromopyridine-3-carbaldehyde 
• 100949-02-8 5-vinylnicotinonitrile 
• 35590-37-5 5-bromopyridine-3-carbonitrile 

Downstream Products

• 135124-71-9 5-(hydroxymethyl)pyridine-3-carbonitrile 
• 562074-59-3 5-(chloromethyl)nicotinonitrile hydrochloride 

Relevant academic research and scientific papers

PYRIMIDINE DERIVATIVES AS INHIBITORS OF PD1/PD-L1 ACTIVATION

The compounds of Formula Ib, Formula Ia, and Formula I are described herein along with their polymorphs, stereoisomers, tautomers, prodrugs, solvates, and pharmaceutically acceptable salts thereof. The process of preparation of the compounds of Formula Ib, Formula Ia, and Formula I is also described. The compounds described herein, their polymorphs, stereoisomers, tautomers, prodrugs, solvates, and pharmaceutically acceptable salts thereof are 2-(benzyloxy)pyrimidine derivatives that are inhibitors of PD-1/PD-L1 activation.

BICYCLIC COMPOUNDS AS INHIBITORS OF PD1/PD-L1 INTERACTION/ACTIVATION

The compounds of Formula I is described herein along with their polymorphs, stereoisomers, tautomers, prodrugs, solvates, and pharmaceutically acceptable salts thereof. The compounds described herein, their polymorphs, stereoisomers, tautomers, prodrugs, solvates, and pharmaceutically acceptable salts thereof are bicyclic compounds that are inhibitors of PD-1/PD-L1 interaction/activation.

ISOXAZOLIDINE DERIVED INHIBITORS OF RECEPTOR INTERACTING PROTEIN KINASE 1 (RIPK 1)

The present disclosure relates generally to methods and compositions for preventing or arresting cell death and/or inflammation.

Antiprotozoal activity of dicationic 3,5-diphenylisoxazoles, their prodrugs and aza-analogues

Fifty novel prodrugs and aza-analogues of 3,5-bis(4-amidinophenyl)isoxazole and its derivatives were prepared. Eighteen of the 24 aza-analogues exhibited IC50 values below 25 nM against Trypanosoma brucei rhodesiense or Plasmodium falciparum. S

Substituted 4-aryl-4h-pyrrolo[2,3-h]chromenes and analogs as activators of caspases and inducers of apoptosis and the use thereof

The present invention is directed to substituted 4H-chromenes and analogs thereof, represented by the Formula (I): wherein R1, R3-R5, A, D, Y and Z are defined herein. The present invention also relates to the discovery that compounds having Formula (I) are activators of caspases and inducers of apoptosis. Therefore, the activators of caspases and inducers of apoptosis of this invention can be used to induce cell death in a variety of clinical conditions in which uncontrolled growth and spread of abnormal cells occurs.

Polysubstituted-2-(3-loweralkylamino-2-R1 O-propoxy)pyridines

Novel substituted (3-loweralkylamino-2-R1 O-propoxy)pyridines, their pharmaceutically acceptable salts, certain intermediates and their preparation are disclosed. These pyridines have pharmaceutically useful properties such as β-adrenergic blocking activity.